Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selenium-Containing 1,4-Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple-Negative Breast Cancer Cells.

Drug development research·2026
Same author

Handheld hyperspectral imaging dataset of annual sowthistle and little mallow under abiotic stress for machine learning.

Data in brief·2026
Same author

Microbial dysbiosis in metabolic disorders: linking epigenomic regulation and pathological mechanisms.

Drug discovery today·2026
Same author

Targeting bacitracin resistance-associated histidine kinase (BraS) in MRSA with isatin and indazole derivatives.

Scientific reports·2026
Same author

Laryngeal leishmaniasis presenting with hoarseness in a child from the highland of Nepal: A rare diagnostic challenge.

IDCases·2026
Same author

CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.

Molecular cancer therapeutics·2026

Related Experiment Video

Updated: May 22, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Ethionamide-induced gynecomastia.

Ramakant Dixit1, Jacob George, Arun K Sharma

  • 1Department of Respiratory Medicine, J. L. N. Medical College, Ajmer, India.

Journal of Pharmacology & Pharmacotherapeutics
|May 26, 2012
PubMed
Summary
This summary is machine-generated.

Gynecomastia is a rare side effect of antituberculosis drugs. A patient developed painful gynecomastia from ethionamide, a second-line drug for multidrug-resistant tuberculosis, which resolved after discontinuation.

Keywords:
Antituberculosis therapydrug-induced gynecomastiaethionamide

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Experiment Videos

Last Updated: May 22, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Area of Science:

  • Endocrinology
  • Pharmacology
  • Infectious Diseases

Background:

  • Antituberculosis chemotherapy, particularly second-line agents, can present with endocrine-related side effects.
  • Gynecomastia, the enlargement of male breast tissue, is an uncommon adverse effect associated with certain medications.
  • Multidrug-resistant tuberculosis (MDR-TB) requires complex treatment regimens often involving second-line drugs with potential toxicity.

Observation:

  • A 38-year-old male patient undergoing treatment for multidrug-resistant pulmonary tuberculosis developed painful gynecomastia.
  • The patient was receiving second-line antituberculosis drugs, including ethionamide.
  • The gynecomastia emerged as an adverse reaction during the course of the chemotherapy.

Findings:

  • The gynecomastia in this patient was directly linked to the administration of ethionamide.
  • Discontinuation of ethionamide led to the complete resolution of the painful gynecomastia.
  • This case supports the rare association between ethionamide and drug-induced gynecomastia.

Implications:

  • Clinicians should be vigilant for endocrine side effects, such as gynecomastia, in patients treated with ethionamide for MDR-TB.
  • Ethionamide should be considered a potential causative agent for drug-induced gynecomastia in the context of tuberculosis treatment.
  • Further investigation into the mechanisms of ethionamide-induced gynecomastia may inform safer treatment strategies for MDR-TB.